Compounds > tiprotimod
Page last updated: 2024-11-06

tiprotimod

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Tiprotimod is a synthetic immunomodulatory drug with a complex chemical structure. It is a derivative of the natural product propolis, a resinous substance collected by honeybees. Tiprotimod has been shown to stimulate the immune system, particularly T-cell proliferation and cytokine production, leading to enhanced immune responses. It has been studied for its potential therapeutic effects in various diseases, including chronic obstructive pulmonary disease (COPD), cancer, and HIV infection. The exact mechanism of action of tiprotimod is not fully understood, but it is believed to involve the activation of toll-like receptor 4 (TLR4), a key player in innate immunity. Tiprotimod is currently undergoing clinical trials for the treatment of COPD, and further research is needed to investigate its efficacy and safety in other conditions.'
```

tiprotimod: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID65890
CHEMBL ID2107097
SCHEMBL ID1684013
MeSH IDM0169708

Synonyms (17)

Synonym
4-[5-(carboxymethyl)-4-methyl-thiazol-2-yl]sulfanylbutanoic acid
105523-37-3
2-(3-carboxy-1-propylthio)-4-methyl-1,3-thiazole]acetic acid
tiprotimod
4-[[5-(carboxymethyl)-4-methyl-1,3-thiazol-2-yl]sulfanyl]butanoic acid
unii-fz7zh245co
2-((3-carboxypropyl)thio)-4-methyl-5-thiazoleacetic acid
5-thiazoleacetic acid, 2-((3-carboxypropyl)thio)-4-methyl-
tiprotimod [inn]
tiprotimodum
tiprotimodum [latin]
fz7zh245co ,
CHEMBL2107097
SCHEMBL1684013
hbw 538
DTXSID90147190
Q27278346
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (5)

TimeframeStudies, This Drug (%)All Drugs %
pre-19904 (80.00)18.7374
1990's1 (20.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.51

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.51 (24.57)
Research Supply Index1.79 (2.92)
Research Growth Index4.31 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.51)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other5 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
ketoconazole
1-acetyl-4-(4-{[2-(2,4-dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy}phenyl)piperazine : A dioxolane that is 1,3-dioxolane which is substituted at positions 2, 2, and 4 by imidazol-1-ylmethyl, 2,4-dichlorophenyl, and [para-(4-acetylpiperazin-1-yl)phenoxy]methyl groups, respectively.		1.9710dichlorobenzene;
dioxolane;
ether;
imidazoles;
N-acylpiperazine;
N-arylpiperazine
thiazoles
[no description available]		3.07501,3-thiazoles;
mancude organic heteromonocyclic parent;
monocyclic heteroarene
nitroblue tetrazolium
Nitroblue Tetrazolium: Colorless to yellow dye that is reducible to blue or black formazan crystals by certain cells; formerly used to distinguish between nonbacterial and bacterial diseases, the latter causing neutrophils to reduce the dye; used to confirm diagnosis of chronic granulomatous disease.		1.9710organic cation
cefodizime
cefodizime: RN given refers to (6R-(6alpha,7beta(Z)))-isomer. cefodizime : A cephalosporin compound having 5-(carboxymethyl)-4-methyl-1,3-thiazol-2-yl]sulfanyl}methyl and [2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetyl]amino side groups located at positions 3 and 7 respectively.		1.98101,3-thiazoles;
cephalosporin;
oxime O-ether		antibacterial drug;
EC 1.14.18.1 (tyrosinase) inhibitor
cefotaxime
Cefotaxime: Semisynthetic broad-spectrum cephalosporin.. cefotaxime : A cephalosporin compound having acetoxymethyl and [2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetyl]amino side groups.		1.98101,3-thiazoles;
cephalosporin;
oxime O-ether		antibacterial drug;
drug allergen
ConditionIndicatedRelationship StrengthStudiesTrials
Candida Infection
[description not available]		02.3820
Candidiasis
Infection with a fungus of the genus CANDIDA. It is usually a superficial infection of the moist areas of the body and is generally caused by CANDIDA ALBICANS. (Dorland, 27th ed)		02.3820
Delayed Hypersensitivity
[description not available]		02.3820
Blood Poisoning
[description not available]		01.9710
Acquired Autoimmune Hemolytic Anemia
[description not available]		01.9710
B16 Melanoma
[description not available]		01.9710
Anemia, Hemolytic, Autoimmune
Acquired hemolytic anemia due to the presence of AUTOANTIBODIES which agglutinate or lyse the patient's own RED BLOOD CELLS.		01.9710
Sepsis
Systemic inflammatory response syndrome with a proven or suspected infectious etiology. When sepsis is associated with organ dysfunction distant from the site of infection, it is called severe sepsis. When sepsis is accompanied by HYPOTENSION despite adequate fluid infusion, it is called SEPTIC SHOCK.		01.9710